Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

NCT00770081 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Renal Insufficiency

Interventions

DRUG: vildagliptin
DRUG: sitagliptin

Sponsor

Novartis